Summary:
A PHASE 1B STUDY OF THE PHARMACOKINETICS AND SAFETY OF ORAL ALZ-801 IN SUBJECTS WITH ALZHEIMER’S DISEASE WHO ARE CARRIERS OF THE ε4 VARIANT OF THE APOLIPOPROTEIN E GENE (APOE 4 CARRIERS)
Qualified Participants Must:
• Patients is between the ages of 50 and 75 years
•
Has a diagnosis of probable dementia due to Alzheimers disease
Qualified Participants May Receive:
Compensation for time and gas